<DOC>
	<DOCNO>NCT00878995</DOCNO>
	<brief_summary>RATIONALE : Testosterone may lessen weight loss improve muscle size strength patient cachexia caused cancer . PURPOSE : This randomized phase I trial study whether testosterone administer standard care chemotherapy and/or radiation work help patient squamous cell carcinoma maintain body weight muscle size strength treatment .</brief_summary>
	<brief_title>Testosterone Treating Cachexia Patients With Squamous Cell Carcinoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine effect testosterone therapy lean body mass muscle strength patient advance recurrent squamous cell carcinoma . - To determine testosterone therapy inflammatory biomarkers patient advance recurrent squamous cell carcinoma . OUTLINE : Patients stratify accord age disease stage . Patients randomize 1 2 treatment arm . - Arm I : Patients receive standard care chemotherapy and/or radiation placebo testosterone intramuscularly ( IM ) weekly 7 week . - Arm II : Patients receive standard care chemotherapy and/or radiation testosterone IM weekly 7 week . Patients undergo dual energy x-ray absorptiometry , muscle strength test , stable isotope metabolic study , indirect calorimetry study , assessment physical activity level , nutritional counseling . Patients also complete mood , fatigue , quality-of-life questionnaire . Blood , muscle tissue , urine sample collect periodically laboratory study . Samples analyze serum inflammatory biomarkers inflammatory cytokine immunoassay . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Diagnosis advance ( stage IIB , IIIA , IIIB ) recurrent squamous cell carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Mini Mental State Examination score &gt; 23 Pregnancy Evidence hepatitis indicate 3fold increase 2 3 liver enzyme Significant liver , renal , heart disease Diabetes mellitus untreated endocrine disease Polycystic ovary syndrome and/or hyperthecosis Androgen secrete tumor ovary adrenal ovarian tumor ( e.g. , Sertoli Leydig cell tumor ) Nonclassical adrenal hyperplasia Cushing 's syndrome Glucocorticoid resistance Hyperprolactinoma hypothyroidism Lactose intolerance Alcohol drug abuse Recent treatment ( within 3 month ) anabolic steroid Ongoing anticoagulant therapy Any circumstance would preclude study participation , opinion principal investigator study physician</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cachexia</keyword>
	<keyword>advanced head/neck carcinoma</keyword>
	<keyword>recurrent head/neck carcinoma</keyword>
</DOC>